The potential and promise of IL-15 in immuno-oncogenic therapies.
about
Pseudoprogression manifesting as recurrent ascites with anti-PD-1 immunotherapy in urothelial bladder cancer.Trial Watch: Immunostimulation with recombinant cytokines for cancer therapyAvelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer CellsInterleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
P2860
The potential and promise of IL-15 in immuno-oncogenic therapies.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
The potential and promise of IL-15 in immuno-oncogenic therapies.
@en
The potential and promise of IL-15 in immuno-oncogenic therapies.
@nl
type
label
The potential and promise of IL-15 in immuno-oncogenic therapies.
@en
The potential and promise of IL-15 in immuno-oncogenic therapies.
@nl
prefLabel
The potential and promise of IL-15 in immuno-oncogenic therapies.
@en
The potential and promise of IL-15 in immuno-oncogenic therapies.
@nl
P2860
P1433
P1476
The potential and promise of IL-15 in immuno-oncogenic therapies.
@en
P2093
Kimberly S Schluns
Tanya O Robinson
P2860
P304
P356
10.1016/J.IMLET.2017.08.010
P577
2017-08-16T00:00:00Z